iCoat Medical’s product portfolio addresses several health issues that are connected to ischemia reperfusion injury. The table below shows what stage each product candidate has reached in the development cycle.
- ATMIRe – Phase I/IIa (First-in-Human) Double-Blind, Placebo-Controlled, Randomized, Single-Center Trial to Evaluate the Safety and Tolerability of iCM012 for Ex Vivo Kidney Allograft Treatment to Minimize Ischemia-Reperfusion Injury (IRI) and Improve Short- and Long-Term Outcomes after Kidney Transplantation. The patient recruitment was successfully completed in May 2023, and a report with 3-month follow-up data is expected in Q3 2023.
- EMPIRe – Phase IIb/III Trial: An adaptive, double-blind, placebo-controlled, randomized, multicenter study assessing iCM012’s efficacy and safety for ex vivo kidney allograft treatment. Its primary goal is to minimize ischemia-reperfusion injury (IRI) and enhance short- and long-term outcomes post kidney transplantation. Anticipated start: Q1 2024.
For further information, see the press releases.
(1st, 2nd, 3rd generation molecules)